Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY
PATENT APPLICATION
TRANSMITTAL

Attorney Docket No. First Inventor		PC25250A	
		Jie Jack Li	
Title	FUSED TETRAHYDROPY METALLOPROTEINASE	YRIDINE DERIVATIVES AS MATRIX INHIBITORS	
Ever	as Mail I shal No	EF220717498US	

(Only for new nonprovisional applications under 37 CFR 1.53(b)) xpress Maii Labei No. Assistant Commissioner for Patents **APPLICATION ELEMENTS** ADDRESS TO: Box Patent Application Washington, DC 20231 See MPEP chapter 600 concerning utility patent application contents. Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or (Submit an original and a duplicate for fee processing) Computer Program (Appendix) Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission 2. See 37 CFR 1.27. (if applicable, all necessary) 191 Specification [Total Pages 3. [1] Computer Readable Form (CRF) (preferred arrangement set forth below) - Descriptive title of the invention b. Specification Sequence Listing on: - Cross Reference to Related Applications i. CD-ROM or CD-R (2 copies); or - Statement Regarding Fed sponsored R & D Reference to sequence listing, a table, paper or a computer program listing appendix Statements verifying identity of above copies - Background of the Invention - Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) - Detailed Description Assignment Papers (cover sheet & document(s)) - Claim(s) 37 CFR 3.73(b) Statement Power of - Abstract of the Disclosure 10. Attorney (when there is an assignee) English Translation Document (if applicable) Drawing(s) (35 U.S.C. 113) [ Total Sheets Copies of IDS Information Disclosure 3 12. 5. Oath or Declaration [ Total Pages Citations Statement (IDS)/PTO-1449 **Preliminary Amendment** Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 18 completed) Return Receipt Postcard (MPEP 503) 14. (Should be specifically itemized) Certified Copy of Priority Document(s) (if foreign priority is claimed) **DELETION OF INVENTOR(S)** Signed statement attached deleting inventor(s) Request and Certification under 35 U.S.C. 122 named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. Application Data Sheet. See 37 CFR 1.76 17. Other: Certificate of Express Mail 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) of prior application No.: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under 19. CORRESPONDENCE ADDRESS Customer Number or Bar Code Label Correspondence address below & PANDET soon into trong Claude F. Purchase, Jr. Name Warner-Lambert Company 2800 Plymouth Road Address 48105 Ann Arbor State Michigan Zip Code City Country U.S.A. Telephone (734) 622-1692 Fax (734) 622-1553 47,871 Claude F. Purchase, Jr. Registration No. (Attorney/Agent) Name (Print/Type)

08/05/2003 Signature Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time well vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



Approved for use through 04/30/2003. OMB 0651-0035 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

	Applicant	claims	small	entity	status.	See 37	<b>CFR</b>	1.27

**TOTAL AMOUNT OF PAYMENT** 

(\$)	1	19	8.	00
141	•		Ψ.	~

O			
<u> </u>	omplete if Known		
Application Number			
Filing Date			
First Named Inventor	Jie Jack Li		
Examiner Name			
Art Unit			
Attorney Docket No.	PC25250A		

METHOD OF PAYMENT (check all that apply)	pply) FEE CALCULATION (continued)		
Check Credit card Money Other None	ne 3. ADDITIONAL FEES		
Deposit Account:	Large Entity   Small Entity		
Deposit OO 0455	Fee Fee Fee Fee Fee Description	Fee Paid	
Account Number 23-0455	1051 130 2051 65 Surcharge - late filing fee or oath	CC F alu	
Deposit Account Warner-Lambert Company	1052 50 2052 25 Surcharge - late provisional filing fee or cover sheet		
Name	1053 130 1053 130 Non-English specification		
The Commissioner is authorized to: (check all that apply)  Charge fee(s) indicated below  Credit any overpayments	1812 2,520 1812 2,520 For filing a request for ex parte reexamination		
Charge any additional fee(s) during the pendency of this application	1804 920* 1804 920* Requesting publication of SIR prior to	ļ	
Charge fee(s) indicated below, except for the filing fee	Examiner action  1805 1,840* 1805 1,840* Requesting publication of SIR after		
to the above-identified deposit account.	Examiner action		
FEE CALCULATION	1251 110 2251 55 Extension for reply within first month		
1. BASIC FILING FEE	1252 410 2252 205 Extension for reply within second month		
Large Entity Small Entity	1253 930 2253 465 Extension for reply within third month		
Fee Fee Fee Fee Pee Paid Code (\$) Code (\$)	1254 1,450 2254 725 Extension for reply within fourth month		
1001 750 2001 375 Utility filling fee 750.00	1255 1,970 2255 985 Extension for reply within fifth month		
1002 330 2002 165 Design filing fee	1401 320 2401 160 Notice of Appeal		
1003 520 2003 260 Plant filing fee	1402 320 2402 160 Filing a brief in support of an appeal		
1004 750 2004 375 Reissue filing fee	1403 280 2403 140 Request for oral hearing		
1005 160 2005 80 Provisional filing fee	1451 1,510 1451 1,510 Petition to institute a public use proceeding		
SUBTOTAL (1) (\$) 750.00	1452 110 2452 55 Petition to revive - unavoidable		
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1453 1,300 2453 650 Petition to revive - unintentional		
Fee from	1501 1,500 2501 650 Office state (of reissue)		
Total Claims 14 -20** = 0 X 0 = 0	7  ····   ···   ···   ···		
Independent	1503 630 2503 315 Plant issue fee		
Claims 280 = 108	1460 130 1460 130 Petitions to the Commissioner		
200 1280	1807 50 1807 50 Processing fee under 37 CFR 1.17(q)		
Large Entity   Small Entity Fee Fee Fee Fee Fee Description	1806 180 1806 180 Submission of Information Disclosure Stmt		
Code (\$) Code (\$)	8021 40 8021 40 Recording each patent assignment per property (times number of properties)	l	
1202	1809 750 2809 375 Filing a submission after final rejection		
1203 280 2203 140 Multiple dependent claim, if not paid	(37 CFR 1.129(a)) d 1810 750 2810 375 For each additional invention to be		
1204 84 2204 42 ** Reissue independent claims over original patent	examined (37 CFR 1.129(b)) 1801 750 2801 375 Request for Continued Examination (RCE)		
1205 18 2205 9 ** Reissue claims in excess of 20	1801 750 2801 375 Request for Continued Examination (RCE) 1802 900 1802 900 Request for expedited examination		
and over original patent	of a design application		
SUBTOTAL (2) (\$) 448.00	Other fee (specify)		
**or number previously paid, if greater; For Reissues, see above	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 0		

SUBMITTED BY (Complete (if applicable) Claude F. Purchase, Jr. Registration No. Name (Print/Type) 47,871 Telephone 734 622-1692 UNCUARUSE Signature Date August 5, 2003

> WARNING: Inf rmati n n this form may bec me public. Credit card inf rmation sh uld not be included on this form. Provide or diticard information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10) Applicant(s): Jie Jack Li				
Filing Date	Examiner	Group Art		
RIDINE DERIVATIVES AS MATRI	X METALLOPROTEINASE IN	NHIBITORS		
UTILITY PATENT APPLICATION				
	(Identify type of correspondence)			
United States Postal Service "Expr	ress Mail Post Office to Addre	essee" service under		
e addressed to: MS Patent Application	n, Commissioner for Patents, P.O. F	 3ox 1450, Alexandria, VA 22313-1450		
		ļ		
<del></del>				
	(Typed or Printed Name of Owe) (Signature of Perso	or Mailing Correspondence)  1326498US  Mailing Label Number)		
Note: Each paper must have i	its own certificate of mailing			
- '	TRIDINE DERIVATIVES AS MATRI  UTILITY PATENT APPLICATION  United States Postal Service "Exprise addressed to: MS Patent Application	Filing Date Examiner  TRIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE IN  UTILITY PATENT APPLICATION  (Identify type of correspondence)  United States Postal Service "Express Mail Post Office to Addressed to: MS Patent Application, Commissioner for Patents, P.O. B  Nanc  (Typed or Printed Name of Commissioner of Person (Signature of Person (Si		